Effects of Aromatase Inhibition in Elderly Men with Low or Borderline-Low Serum Testosterone Levels
The DOI matches its Crossref record; 63 of the 68 references it cites were found in a registry or an index.
Abstract
As men age, serum testosterone levels decrease, a factor that may contribute to some aspects of age-related physiological deterioration. Although androgen replacement has been shown to have beneficial effects in frankly hypogonadal men, its use in elderly men with borderline hypogonadism is controversial. Furthermore, current testosterone replacement methods have important limitations. We investigated the ability of the orally administered aromatase inhibitor, anastrozole, to increase endogenous testosterone production in 37 elderly men (aged 62–74 yr) with screening serum testosterone levels less than 350 ng/dl. Subjects were randomized in a double-blind fashion to the following 12-wk oral regimens: group 1: anastrozole 1 mg daily (n = 12); group 2: anastrozole 1 mg twice weekly (n = 11); and group 3: placebo daily (n = 14). Hormone levels, quality of life (MOS Short-Form Health Survey), sexual function (International Index of Erectile Function), benign prostate hyperplasia severity (American Urological Association Symptom Index Score), prostate-specific antigen, and measures of safety were compared among groups. Mean ± sd bioavailable testosterone increased from 99 ± 31 to 207 ± 65 ng/dl in group 1 and from 115 ± 37 to 178 ± 55 ng/dl in group 2 (P < 0.001 vs. placebo for both groups and P = 0.054 group 1 vs. group 2). Total testosterone levels increased from 343 ± 61 to 572 ± 139 ng/dl in group 1 and from 397 ± 106 to 520 ± 91 ng/dl in group 2 (P < 0.001 vs. placebo for both groups and P = 0.012 group 1 vs. group 2). Serum estradiol levels decreased from 26 ± 8 to 17 ± 6 pg/ml in group 1 and from 27 ± 8 to 17 ± 5 pg/ml in group 2 (P < 0.001 vs. placebo for both groups and P = NS group 1 vs. group 2). Serum LH levels increased from 5.1 ± 4.8 to 7.9 ± 6.5 U/liter and from 4.1 ± 1.6 to 7.2 ± 2.8 U/liter in groups 1 and 2, respectively (P = 0.007 group 1 vs. placebo, P = 0.003 group 2 vs. placebo, and P = NS group 1 vs. group 2). Scores for hematocrit, MOS Short-Form Health Survey, International Index of Erectile Function, and American Urological Association Symptom Index Score did not change. Serum prostate-specific antigen levels increased in group 2 only (1.7 ± 1.0 to 2.2 ± 1.5 ng/ml, P = 0.031, compared with placebo). These data demonstrate that aromatase inhibition increases serum bioavailable and total testosterone levels to the youthful normal range in older men with mild hypogonadism. Serum estradiol levels decrease modestly but remain within the normal male range. The physiological consequences of these changes remain to be determined.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These compounds have been shown to raise testosterone levels in hypogonadal men and are also orally administered (64-66).”
From Non-testosterone management of male hypogonadism: an examination of the existing literature (2020) · cites this paper as [65]
In the citing paper
“Aromatase inhibitors effectively delay epiphysial maturation in boys and improve testosterone levels in adult men”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [29]
In the citing paper
“In men third-generation aromatase inhibitors will decrease the mean plasma estradiol/testosterone ratio by 77% [28,29].”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [29]
In the citing paper
“Lowering estradiol levels, by administering an aromatase inhibitor, is associated with an increase in levels of LH, follicle-stimulating hormone (FSH) and testosterone [28,29].”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [29]
In the citing paper
“Although aromatase inhibition by anastrozole and letrozole is reported to be close to 100%, administration of these inhibitors to men will not suppress plasma estradiol levels completely.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [29]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., & Mishra, A. (1997) · Urology · doi:10.1016/s0090-4295(97)00238-0 · Cited by 5,849
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
Feldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861
Self-citationGRAY, A., FELDMAN, H. A., MCKINLAY, J. B., & LONGCOPE, C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-1016 · Cited by 1,118
Self-citationTestosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial
Sih, R. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.6.1661 · Cited by 922
Morley, J. E., Kaiser, F. E., Perry, H. M., Patrick, P., Morley, P. M. K., Stauber, P. M., Vellas, B., Baumgartner, R. N., & Garry, P. J. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90057-3 · Cited by 830
Effects of testosterone supplementation in the aging male
Tenover, J. S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1092 · Cited by 768
Falahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757
van den Beld, A. W. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.9.3276 · Cited by 622
Effect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.8.2647 · Cited by 531
Ferrini, R. L., & Barrett-Connor, E. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009519 · Cited by 473
Effects of Testosterone Replacement Therapy in Old Hypogonadal Males: A Preliminary Study
Morley, J. E., Perry, H. M., Kaiser, F. E., Kraenzle, D., Jensen, J., Houston, K., Mattammal, M., & Perry, H. M. (1993) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1993.tb02049.x · Cited by 463
Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.6.1966 · Cited by 460
Kenny, A. M., Prestwood, K. M., Gruman, C. A., Marcello, K. M., & Raisz, L. G. (2001) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/56.5.m266 · Cited by 456
Vermeulen, A., Kaufman, J. M., Goemaere, S., & Van Pottelberg, I. (2002) · The Aging Male · doi:10.1080/tam.5.2.98.102 · Cited by 452
AROMATASE INHIBITORS FOR MALE INFERTILITY
Raman, J. D., & Schlegel, P. N. (2002) · Journal of Urology · doi:10.1016/s0022-5347(01)69099-2 · Cited by 383
Leydig Cell Function in Normal Men: Effect of Age, Life-Style, Residence, Diet, and Activity*
DESLYPERE, J. P., & VERMEULENf, A. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-5-955 · Cited by 343
Outcomes of Long-Term Testosterone Replacement in Older Hypogonadal Males: A Retrospective Analysis
Hajjar, R. R., Kaiser, F. E., & Morley, J. E. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.11.3793 · Cited by 325
Secondary Hypogonadism in Older Men: Its Relation to Impotence*
KORENMAN, S. G., MORLEY, J. E., MOORADIAN, A. D., DAVIS, S. S., KAISER, F. E., SILVER, A. J., VIOSCA, S. P., & GARZA, D. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-4-963 · Cited by 320
Gray, A., Berlin, J. A., McKinlay, J. B., & Longcope, C. (1991) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(91)90028-8 · Cited by 316
Self-citationCHANGES IN THE PITUITARY‐TESTICULAR SYSTEM WITH AGE
BAKER, H. W. G., BURGER, H. G., de KRETSER, D. M., HUDSON, B., O'CONNOR, S., WANG, C., MIROVICS, A., COURT, J., DUNLOP, M., & RENNIE, G. C. (1976) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1976.tb01964.x · Cited by 306
Differential Effects of Androgens and Estrogens on Bone Turnover in Normal Men
Leder, B. Z., LeBlanc, K. M., Schoenfeld, D. A., Eastell, R., & Finkelstein, J. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021036 · Cited by 283
Self-citationAromatase Inhibition in the Human Male Reveals a Hypothalamic Site of Estrogen Feedback
Hayes, F. J. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.9.3027 · Cited by 265
FINKELSTEIN, J. S., WHITCOMB, R. W., O’DEA, L. S. L., LONGCOPE, C., SCHOENFELD, D. A., & CROWLEY, W. F. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-3-609 · Cited by 265
Self-citationBURRIS, A. S., BANKS, S. M., CARTER, C. S., DAVIDSON, J. M., & SHERINS, R. J. (1992) · Journal of Andrology · doi:10.1002/j.1939-4640.1992.tb00319.x · Cited by 259
Arimidex�: A potent and selective fourth-generation aromatase inhibitor
Plourde, P. V., Dyroff, M., & Dukes, M. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00682745 · Cited by 258
Bhasin, S., Singh, A. B., Mac, R. P., Carter, B., Lee, M. I., & Cunningham, G. R. (2003) · Journal of Andrology · doi:10.1002/j.1939-4640.2003.tb02676.x · Cited by 221
Impotence and Aging: Clinical and Hormonal Factors
Kaiser, F. E., Viosca, S. P., Morley, J. E., Mooradian, A. D., Davis, S. S., & Korenman, S. G. (1988) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1988.tb04021.x · Cited by 220
Estrogen Suppression in Males: Metabolic Effects1
Mauras, N., O’Brien, K. O., Klein, K. O., & Hayes, V. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6676 · Cited by 190
Testosterone Deficiency As a Risk Factor for Hip Fractures in Men: A Case-Control Study
Jackson, J. A., Riggs, M. W., & Spiekerman, A. M. (1992) · The American Journal of the Medical Sciences · doi:10.1097/00000441-199207000-00003 · Cited by 183
Androgen–Behavior Correlations in Hypogonadal Men and Eugonadal Men
Alexander, G. M., Swerdloff, R. S., Wang, C., Davidson, T., McDonald, V., Steiner, B., & Hines, M. (1998) · Hormones and Behavior · doi:10.1006/hbeh.1998.1439 · Cited by 180
Kenny, A. M., Bellantonio, S., Gruman, C. A., Acosta, R. D., & Prestwood, K. M. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.5.m321 · Cited by 177
McPherson, S. J. (2001) · Endocrinology · doi:10.1210/en.142.6.2458 · Cited by 176
Cohen, P. G. (2001) · Medical Hypotheses · doi:10.1054/mehy.2000.1169 · Cited by 172
FINKELSTEIN, J. S., O’DEA, L. S. L., WHITCOMB, R. W., & CROWLEY, W. F. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-3-621 · Cited by 169
The gonadotropin-suppressive activity of androgen is increased in elderly men
Winters, S. J., Sherins, R. J., & Troen, P. (1984) · Metabolism · doi:10.1016/0026-0495(84)90237-3 · Cited by 154
Oestrogens and prostate cancer.
Risbridger, G. P., Bianco, J. J., Ellem, S. J., & McPherson, S. J. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100187 · Cited by 139
Testosterone Supplementation in Older Men: A Rational Idea Whose Time Has Not Yet Come
BHASIN, S., & BUCKWALTER, J. G. (2001) · Journal of Andrology · doi:10.1002/j.1939-4640.2001.tb02570.x · Cited by 135
Androgen Replacement Therapy and Prostate Safety
Morales, Á. (2002) · European Urology · doi:10.1016/s0302-2838(01)00039-2 · Cited by 112
Taxel, P., Kennedy, D. G., Fall, P. M., Willard, A. K., Clive, J. M., & Raisz, L. G. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7541 · Cited by 111
The measurement of sex steroid binding globulin by differential ammonium sulphate precipitation
O'connor, S., Baker, H. W. G., Dulmanis, A., & Hudson, B. (1973) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(73)90002-2 · Cited by 107
Estrogen Suppression in Males: Metabolic Effects
Mauras, N. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.7.2370 · Cited by 107
Behavioural correlates of testosterone
Christiansen, K. (1998) · Springer eBooks · doi:10.1007/978-3-642-72185-4_3 · Cited by 103
Kaufman, J., & Vermeulen, A. (1998) · Springer eBooks · doi:10.1007/978-3-642-72185-4_16 · Cited by 103
Age-related decline of plasma bioavailable testosterone in adult men
NAHOUL, K., & Roger, M. (1990) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(90)90287-3 · Cited by 100
Citron, J. T., Ettinger, B., Rubinoff, H., Ettinger, V. M., Minkoff, J., Hom, F., Kan, P., & Alloo, R. (1996) · Journal of Urology · doi:10.1016/s0022-5347(01)66441-3 · Cited by 89
Estrogenic effects on prostatic differentiation and carcinogenesis
Cunha, G. R., Wang, Y. Z., Hayward, S. W., & Risbridger, G. P. (2001) · Reproduction Fertility and Development · doi:10.1071/rd01010 · Cited by 86
Estradiol modulates the pulsatile secretion of biologically active luteinizing hormone in man.
Veldhuis, J. D., & Dufau, M. L. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113115 · Cited by 81
Denti, L., Pasolini, G., Sanfelici, L., Benedetti, R., Cecchetti, A., Ceda, G. P., Ablondi, F., & Valenti, G. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb03028.x · Cited by 65
Habenicht, U., Schwarz, K., Neumann, F., & El Etreby, M. F. (1987) · The Prostate · doi:10.1002/pros.2990110404 · Cited by 63
Wiseman, L. R., & Adkins, J. C. (1998) · Drugs & Aging · doi:10.2165/00002512-199813040-00008 · Cited by 58
Testicular endocrine function in the ageing male
Vermeulen, A., & Deslypère, J. P. (1985) · Maturitas · doi:10.1016/0378-5122(85)90050-7 · Cited by 56
Taxel, P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.6.2869 · Cited by 53
Schnorr, J. A., Bray, M. J., & Veldhuis, J. D. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7520 · Cited by 49
Pharmacology and clinical uses of testosterone
Nieschlag, E., & Behre, H. M. (1998) · Springer eBooks · doi:10.1007/978-3-642-72185-4_10 · Cited by 46
CLINICAL MANIFESTATIONS OF BENIGN PROSTATIC HYPERPLASIA
Madsen, F. A., & Bruskewitz, R. C. (1995) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)00665-0 · Cited by 44
Meikle, A. W. (1998) · Springer eBooks · doi:10.1007/978-3-642-72185-4_14 · Cited by 44
Ageing, hormones, body composition, metabolic effects
Vermeulen, A. (2002) · World Journal of Urology · doi:10.1007/s00345-002-0257-4 · Cited by 39
Finkelstein, J. S. (1998) · Springer eBooks · doi:10.1007/978-3-642-72185-4_6 · Cited by 37
Suzuki, K., Takezawa, Y., Suzuki, T., Honma, S., & Yamanaka, H. (1994) · The Prostate · doi:10.1002/pros.2990250402 · Cited by 34
Bhasin, S., Bross, R., Storer, T. W., & Casaburi, R. H. (1998) · Springer eBooks · doi:10.1007/978-3-642-72185-4_7 · Cited by 27
Research works printed but not linked: 1
- Med Lett Drugs Ther, 42, 49
Cited by
The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications
Kaufman, J. M., & Vermeulen, A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0013 · Cited by 1,079
Epoxide hydrolases: their roles and interactions with lipid metabolism
Newman, J. W., Morisseau, C., & Hammock, B. D. (2005) · Progress in Lipid Research · doi:10.1016/j.plipres.2004.10.001 · Cited by 474
Oestrogens and spermatogenesis
Carreau, S., & Hess, R. A. (2010) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2009.0235 · Cited by 307
Traish, A. M., Goldstein, I., & Kim, N. N. (2007) · European Urology · doi:10.1016/j.eururo.2007.02.034 · Cited by 268
Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T.-P., Valkonen, V.-P., & Salonen, J. T. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0970 · Cited by 230
“Consistent with this hypothesis, the aromatase inhibitor anastrozole has been shown to increase total and bioavailable testosterone levels in elderly men with low testosterone levels (47).”
Background
Metadata
- Authors
- Leder, B. Z., Rohrer, J. L., Rubin, S. D., Gallo, J., & Longcope, C.
- Affiliations
- Massachusetts General Hospital (US)
- AstraZeneca (United States) (US)
- AstraZeneca Pharmaceuticals (S.D.R., J.G.), Wilmington, Delaware 19850
- University of Massachusetts Chan Medical School (US)
- ORCID
- Leder, Benjamin Z.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-03-01
- Volume
- 89
- Issue
- 3
- Pages
- 1174-1180
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2117332496
- Semantic Scholar
- aedcb017eb7fc20eca8962b9ec633cc90042cd64
- Cited by
- 149
- References
- 68
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 6 · 2023: 3 · 2022: 6 · 2021: 5 · 2020: 7 · 2019: 8 · 2018: 5 · 2017: 3 · 2016: 10 · 2015: 8 · 2014: 7 · 2013: 6 · 2012: 5
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (K23 RR 16310, K23RR016310)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Keywords
- anastrozole, aromatase inhibitors, older men, androgen deficiency, testosterone replacement therapy, estradiol suppression, luteinizing hormone, sexual function, erectile function, benign prostatic hyperplasia, quality of life, adverse effects, drug safety, age-related testosterone decline, prostate-specific antigen, LH/FSH ratio
- MeSH terms
- Anastrozole, Aged, Aging, Enzyme Inhibitors, Estrogens, Humans, Hypogonadism, Male, Middle Aged, Nitriles, Quality of Life, Testosterone, Triazoles, Treatment Outcome, Aromatase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.